A composition having an intestinal injury repair function and a method of preparing the same

Abstract

The application relates to the field of traditional Chinese medicine, in particular to a composition with intestinal injury repair function and a preparation method thereof, wherein the formula of the composition comprises inulin, melon extract, turmeric powder, pueraria powder, quercetin, jujube fruit, artichoke powder and the like; and the composition has the intestinal injury repair function.

Description

Technical Field

[0001] This invention relates to the field of traditional Chinese medicine applications, specifically to a composition with intestinal damage repair function and its preparation method. Background Technology

[0002] Intestinal injury is a common pathological phenomenon in clinical practice, and its causes are complex and diverse. It mainly includes chemical damage (such as mucosal barrier damage caused by chemotherapy drugs and alcohol intake), radiation damage (apoptosis of intestinal epithelial cells caused by the large generation of free radicals during tumor radiotherapy), and chronic intestinal inflammation (such as inflammatory bowel disease).

[0003] In recent years, with economic development, people have gradually sought treatment methods with fewer side effects on the body to repair intestinal damage.

[0004] Therefore, developing a composition derived from natural plants for the treatment or prevention of intestinal damage is of great significance and commercial value in this field. Summary of the Invention

[0005] To address the aforementioned technical problems and overcome the shortcomings of existing technologies, this invention provides a composition with intestinal damage repair function and its preparation method. This composition possesses intestinal damage repair function.

[0006] The present invention solves the above-mentioned technical problems through the following technical solutions.

[0007] This invention provides a composition with intestinal damage repair function, the formulation of which includes: inulin, melon extract, turmeric powder, kudzu root powder, quercetin, Japanese raisin tree fruit, artichoke powder and component I; wherein, component I is obtained by the following preparation method: volatile oil is extracted from angelica, chuanxiong and costus root by steam distillation, and then the volatile oil is ground and encapsulated with oligofructose.

[0008] In this invention, the formula comprises: 2-5 parts inulin, 1-3 parts melon extract, 0.5-2 parts turmeric powder, 0.5-2 parts kudzu root powder, 2-5 parts quercetin, 2-5 parts Japanese raisin tree fruit, 2-5 parts artichoke powder, and 2-5 parts component I.

[0009] In this invention, the weight ratio of Angelica sinensis, Ligusticum chuanxiong and Aucklandia lappa in component I is 1:(0.6-1):(0.1-0.4); preferably 1:0.8:0.25.

[0010] In this invention, in component I, the weight ratio of the volatile oil to the fructooligosaccharide is 1:(2-5); preferably 1:3.

[0011] The present invention also provides a method for preparing a composition with intestinal damage repair function, which is prepared by the following preparation steps: S1: volatile oil is extracted from Angelica sinensis, Ligusticum chuanxiong and Aucklandia lappa by steam distillation, and then the volatile oil is ground and encapsulated with oligofructose to obtain component I.

[0012] S2: Grind and mix inulin, melon extract, turmeric powder, kudzu root powder, quercetin, Japanese raisin tree fruit, artichoke powder and component I evenly to obtain the composition with intestinal damage repair function.

[0013] The present invention also provides the use of the above composition in the preparation of products for treating enteritis.

[0014] Without violating common sense in the field, the above-mentioned preferred conditions can be combined arbitrarily to obtain various preferred embodiments of the present invention.

[0015] The reagents and raw materials used in this invention are all commercially available.

[0016] The positive and progressive effects of the present invention are as follows: The present invention provides a composition with intestinal damage repair function, which has intestinal damage repair function. Attached Figure Description

[0017] Figure 1 Phenotypic diagram showing the promoting effect of the composition on the resolution of colitis inflammation.

[0018] Figure 2 The effect of oral administration of the test substance for 9 consecutive days on feces of mice with DSS-induced ulcerative colitis.

[0019] Figure 3 The colonic H&E staining pathology of mice with DSS-induced ulcerative colitis was observed under a microscope after oral administration of the test substance for 9 days. Detailed Implementation

[0020] The present invention is further illustrated below by way of embodiments, but the invention is not limited to the scope of the embodiments described herein. Experimental methods in the following embodiments that do not specify specific conditions were performed under conventional conditions or as selected according to the product instructions.

[0021] Example 1: Preparation of component I containing volatile oil: by weight: 1 part Angelica sinensis, 0.8 parts Ligusticum chuanxiong and 0.25 parts Aucklandia lappa were used to extract volatile oil by steam distillation. 1 part of volatile oil was ground and encapsulated with 3 parts of fructooligosaccharides to obtain component I.

[0022] Preparation of a composition with intestinal damage repair function: By weight: 3 parts inulin, 1.5 parts melon extract, 1 part turmeric powder, 1 part kudzu root powder, 3 parts quercetin, 3 parts Japanese raisin tree fruit and 3 parts artichoke powder are ground and stirred evenly. After sterilization at 120°C, 2 parts of component I are added and ground and mixed evenly to obtain composition 1.

[0023] Example 2: Experimental objective: To evaluate the therapeutic effect of the composition on zebrafish colitis.

[0024] Experimental animals: Transgenic neutrophilic fluorescent zebrafish, which reproduced naturally by mating in pairs, totaling 80 fish, with 20 fish in each experimental group, aged 3 days after fertilization. They were housed in fish tank water at 28 ℃ (water quality: 200 mg of readily soluble sea salt added per 1 L of reverse osmosis water, conductivity 480~510 μS / cm; pH 6.9~7.2).

[0025] Experimental reagents: The composition was prepared as a stock solution with ultrapure water to a concentration of 100 mg / mL immediately before use. Trinitrobenzenesulfonic acid (TNBS), a brown liquid with a concentration of 4 μM.

[0026] Model creation: A zebrafish colitis model was established by treating 3dpf transgenic neutrophil fluorescent zebrafish with 4 μM TNBS for 48 h.

[0027] Concentration group: Normal group: Normal zebrafish were fed normally.

[0028] Model group: Zebrafish with colitis were fed normally.

[0029] Treatment group: Zebrafish with colitis were fed normally while being treated with 0.2 mg / mL of composition 1.

[0030] Treatment group 2: The zebrafish model of colitis were fed normally while being treated with 0.4 mg / mL of composition 1.

[0031] For each of the above experimental groups, 20 transgenic neutrophil-positive fluorescent zebrafish were treated; 12 zebrafish from each group were randomly selected for observation, photography, and image preservation under a fluorescence microscope. The phenotypic effect of the composition on the resolution of colitis inflammation is shown in the figure below. Figure 1 As shown, the distribution of neutrophils in colitis tissue was quantified using image analysis software, and the statistical results were analyzed using... ± SE represents the percentage of positive results. The formula for calculating the composition's effect on inflammation reduction is as follows, and the statistical results are shown in Table 1: .

[0032] Table 1:

[0033] .

[0034] According to the experimental results in Table 1, the number of neutrophils in the intestine of zebrafish in the model group (10.3) was significantly lower than that in the normal group (1.4), p<0.001, indicating that the model was successfully established.

[0035] The experimental results of treatment group 1 and treatment group 2 showed that the composition at concentrations of 0.2 mg / mL and 0.4 mg / mL promoted the reduction of inflammation in colitis by 37% and 78%, respectively. Compared with the model control group, the results showed that the composition had a significant effect on reducing colitis inflammation.

[0036] Example 3: Experimental objective: To evaluate the therapeutic effect of the test substance on DSS-induced ulcerative colitis in mice.

[0037] Preparation of reagents and materials: Preparation of 3.5% DSS solution: Dissolve 35g of DSS in 1000ml of sterile water to prepare a 3.5% DSS solution. Prepare 1000ml each time and distribute it evenly into the drinking bottles of each cage of mice. Prepare once every two days.

[0038] Test substance preparation: Dissolve the test substance in PBS (pH 7.2) to prepare three strengths: A, B, and C. Specifically: A: Low dose of test substance: 0.2 mg / ml; B: Medium dose of test substance: 0.4 mg / ml; C: High dose of test substance: 0.8 mg / ml.

[0039] Preparation of positive control drug: Prepare a solution of sulfasalazine in CMC-Na at a concentration of 0.8 mg / mL.

[0040] Laboratory animal housing: SPF-grade male C57BL / 6 mice; Source: Beijing Vital River Laboratory Animal Technology Co., Ltd.; Number of animals: 60 mice that met the experimental requirements and were in good health were selected for the experiment.

[0041] Food and water: During the adaptation period, feed SPF rats and mice with growth and reproduction diet (Co). 60 Sterilized water was purchased from Beijing Keao Xieli Feed Co., Ltd. Water used for laboratory animals was autoclaved and filtered.

[0042] Animal selection and fasting: Animals used in experiments will be kept in good health. Animals will have free access to food and water during the experiment.

[0043] Animal grouping: The experiment began after acclimatization. Sixty healthy mice were randomly divided into 6 groups of 10 each, named as blank control group (group 1), model group (group 2), positive control group (group 3), high-dose test substance group (group 4), medium-dose test substance group (group 5), and low-dose test substance group (group 6).

[0044] The dosage and method of administration are shown in Table 2.

[0045] Table 2:

[0046] Experimental Methods: Animals were given free access to 3.5% DSS solution for modeling (day 1 of modeling). The control group was given normal autoclaved water. The modeling solution was changed every 2 days. Modeling was carried out for 7 consecutive days. On day 8, the 3.5% DSS was replaced with drinking water for another 2 days. The weight of the mice was monitored daily; the shape of the feces and the presence of bleeding were observed every two days.

[0047] On the first day of modeling (day 1), the animal was administered via oral gavage at a dose of 0.1 ml / 10 g body weight, once daily for 9 consecutive days (day 1-day 9). On the second day after the last administration (day 10), the animal was dissected, the colon was separated, weighed, and its length was measured. The integrity of the colonic mucosa was observed and photographed. Figure 2 As shown. Subsequently, the colon was fixed in 10% formalin and subjected to H&E pathological staining. The staining results are shown below. Figure 3 As shown.

[0048] according to Figure 2 and Figure 3 It can be seen that the high-dose group of the test substance had the best therapeutic effect, which was better than that of the positive control group of sulfasalazine.

[0049] Example 4: Experimental objective: To evaluate the effect of the test substance on bloody stool symptoms in mice with DSS-induced ulcerative colitis.

[0050] Experimental methods: According to the group assignments, the mice were administered the test substance orally via gavage for 9 consecutive days. The stool shape and presence of bleeding were observed every two days. The intestinal contents exhibited typical fecal characteristics of ulcerative colitis. The experimental results are shown in Table 3.

[0051] Table 3:

[0052] All mice in the model group showed obvious loose stools, and 9 / 10 mice showed obvious bloody stools. The positive control drug sulfasalazine (600 mg / kg) and the high dose of the test substance both improved the symptoms of ulcerative colitis in mice. It can be seen that the composition of the present invention has a therapeutic effect on the bloody stool symptoms of DSS-induced ulcerative colitis in mice.

Claims

1. A composition with intestinal damage repair function, characterized in that, Its formula includes: 2-5 parts inulin, 1-3 parts melon extract, 0.5-2 parts turmeric powder, 0.5-2 parts kudzu root powder, 2-5 parts quercetin, 2-5 parts Japanese raisin tree fruit, 2-5 parts artichoke powder, and 2-5 parts component I; Component I is obtained by the following preparation method: volatile oils are extracted from Angelica sinensis, Ligusticum chuanxiong and Aucklandia lappa by steam distillation, and then the volatile oils are ground and encapsulated with fructooligosaccharides; In component I, the weight ratio of Angelica sinensis, Ligusticum chuanxiong and Aucklandia lappa is 1:(0.6-1):(0.1-0.4).

2. The composition with intestinal damage repair function as described in claim 1, characterized in that, In component I, the weight ratio of Angelica sinensis, Ligusticum chuanxiong, and Aucklandia lappa is 1:0.8:0.

25.

3. The composition with intestinal damage repair function as described in claim 1, characterized in that, In component I, the weight ratio of the volatile oil to the oligofructose is 1:(2-5).

4. A method for preparing a composition with intestinal damage repair function as described in any one of claims 1-3, characterized in that, It is prepared through the following steps: S1: The volatile oils of Angelica sinensis, Ligusticum chuanxiong, and Aucklandia lappa were extracted by steam distillation, and then the volatile oils were ground and encapsulated with fructooligosaccharides to obtain component I; S2: Grind and mix inulin, melon extract, turmeric powder, kudzu root powder, quercetin, Japanese raisin tree fruit, artichoke powder and component I evenly to obtain the composition with intestinal damage repair function.

5. The use of the composition according to any one of claims 1-3 in the preparation of a product for treating enteritis.

Images